Journal
BRAIN RESEARCH BULLETIN
Volume 151, Issue -, Pages 38-45Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2018.11.018
Keywords
Inflammation; Multiple sclerosis; Purinergic receptor
Categories
Funding
- Merck Serono (a business of Merck KGaA, Darmstadt, Germany)
- Spanish Ministry of Science, Innovation and University [SAF2016-75292-R]
- Basque Government
- University of the Basque Country (UPV/EHU)
- Centro de Investigacion Biomedica en Red, Enfermedades Neurodegenerativas (CIBERNED)
Ask authors/readers for more resources
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system, characterized by the presence of focal lesions in white and grey matter with peripheral immune cells infiltration. Purinergic receptors control immune cell function as well as neuronal and oligodendroglial survival, and the activation of astrocytes and microglia, the endogenous brain immune cells. In particular, ionotropic purinergic receptors P2X4 and P2X7 and metabotropic receptor P2Y12 are differently expressed along the disease and their activation or blockage modifies the course of texperimental autoimmune encephalomyelitis (EAE), the dominant animal model of MS. In this review, we will summarize emerging evidence of the role of these three receptor types as potential MS biomarkers and therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available